Thomas F Eleveld

9PUBLICATIONS
27CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsSolid tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Apr 17, 2026
Identification and validation of liquid biopsy-based methylation biomarkers for germ cell tumor subtypes.

|Feb 19, 2026
Impact of Circulating Tumor DNA and Copy-Number Alterations on Clinical Outcome in Relapsed/Refractory Germ Cell Tumors Treated With Salvage High-Dose Chemotherapy.

Milena Urbini, Thomas F Eleveld, Maurizio Polano

|Jul 22, 2025
Low-amplitude copy number gains shape cancer through known and novel oncogenes with associated therapeutic vulnerabilities.

Thomas F Eleveld, Bauke Ylstra, Leendert H J Looijenga

|Jul 12, 2025
Yolk Sac Elements in Tumors Derived from Pluripotent Stem Cells: Borrowing Knowledge from Human Germ Cell Tumors.

Marnix van Soest, Joaquin Montilla-Rojo, Thomas F Eleveld

|Apr 20, 2022
Chromosome 3p25.3 Gain Is Associated With Cisplatin Resistance and Is an Independent Predictor of Poor Outcome in Male Malignant Germ Cell Tumors.

Dennis M Timmerman, Thomas F Eleveld, Sruthi Sriram

|Sep 10, 2021
Recurrence of a Mediastinal Germ-Cell Tumor as a Somatic-Type Malignancy: A Complex Case Report.

Caroline C C Hulsker, Mariëtte E G Kranendonk, Thomas F Eleveld

Pageof 2

Frequent Collaborators

6 joint publications

Leendert H J Looijenga

3 joint publications

Ferdinand W Janssen

2 joint publications

Bauke Ylstra

2 joint publications

Giorgia Gurioli